as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,602.9
Change
+16.7 (1.05%)
Open
₹1,587.0
Prev. Close
₹1,586.2
Day High
₹1,617.4
Day Low
₹1,570.0
Volume Analysis
Traded
126,006
Delivered
60,773
Delivery %
48.23%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (24.0%)
Weaknesses (2)
- •Low return on equity (-1.09%)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (231.6%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,670.94 | ₹1,644.17 | ₹1,623.54 | ₹1,596.77 | ₹1,576.14 | ₹1,549.37 | ₹1,528.74 |
| Fibonacci | ₹1,644.17 | ₹1,626.06 | ₹1,614.88 | ₹1,596.77 | ₹1,578.66 | ₹1,567.48 | ₹1,549.37 |
| Camarilla | ₹1,615.94 | ₹1,611.59 | ₹1,607.25 | ₹1,596.77 | ₹1,598.56 | ₹1,594.21 | ₹1,589.87 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-10.34%
1 Week
-1.06%
1 Month
+18.11%
3 Months
+4.42%
6 Months
-12.62%
1 Year
-4.16%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-0.03%
Net margin -0.12% × asset turnover 0.17x × equity multiplier 1.45x
Company Overview
Sector
Healthcare
Market Cap
₹18,464 Cr
P/E (TTM)
1614.0
ROE
-1.09%
Book Value
₹516.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Onesource Specl Pharma L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Cash Flow (1/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (24.0%); low return on equity (-1.09%); promoter holding is falling. Strong 3-year revenue growth (231.6%).
TopFund Score — Fundamentals Quality
59/100 — AverageData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 3.12 times its book value
- −Company has low interest coverage ratio.
- −Company has a low return on equity of -2.63% over last 3 years.
- −Promoters have pledged 38.8% of their holding.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Company to participate in Jefferies Global Healthcare Conference in London, November 16-19, 2026.
Intimation of Transcript of Earnings call dated October 27, 2026
OneSource receives USFDA EIR with VAI for Bengaluru SPD facility after June 2026 inspection.
Intimation about publication of newspaper advertisement - Extract of unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2026.
Audio recording of Q2 FY27 earnings call held October 27, 2026, made available on website.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 | 516 |
| Expenses + | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 | 353 |
| Operating Profit | -39 | -10 | -3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 | 163 |
| OPM % | -114.0% | -19.0% | -3.8% | 22.0% | 23.0% | 36.0% | 43.0% | 27.0% | 28.0% | 6.0% | 21.0% | 27.0% | 32.0% |
| Other Income + | -32 | -74 | 3 | -1 | -1 | -94 | 2 | 2 | 3 | -2 | 2 | 0 | -1 |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 | 35 |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 | 75 |
| Profit before tax | -114 | -130 | -40 | -47 | -37 | -67 | 83 | -4 | 6 | -93 | 0 | 20 | 53 |
| Tax % | 0.0% | 0.0% | 0.0% | -88.0% | 12.0% | 4.0% | -19.0% | -96.0% | -83.0% | -5.0% | -1,630.0% | -23.0% | -9.0% |
| Net Profit + | -114 | -130 | -40 | -6 | -42 | -69 | 98 | 0 | 10 | -89 | 5 | 25 | 57 |
| EPS in Rs | — | — | — | — | — | -6 | 9 | 0 | 1 | -8 | 0 | 2 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 891 | 598 | 482 | 12 | 12 | -26 | 1 | 37 | 37 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 21 | 132 | 39 | 172 | 1,445 | 1,422 | 1,684 |
| Expenses + | 93 | 229 | 199 | 254 | 978 | 1,117 | 1,288 |
| Operating Profit | -71 | -97 | -161 | -82 | 467 | 304 | 396 |
| OPM % | -334.0% | -73.0% | -415.0% | -48.0% | 32.0% | 21.0% | 24.0% |
| Other Income + | 1 | 4 | -526 | -143 | -94 | 5 | -2 |
| Interest | 16 | 68 | 48 | 89 | 166 | 122 | 126 |
| Depreciation | 34 | 70 | 66 | 76 | 274 | 279 | 288 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -92 | -20 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | -73.0% | -20.0% | — |
| Net Profit + | -121 | -231 | -800 | -391 | -18 | -74 | -2 |
| EPS in Rs | — | — | — | — | -2 | -6 | 0 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 518 | -71 | 344 | 740 | -2 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 | 5,909 |
| Borrowings + | 386 | 1,154 | 864 | 562 | 772 | 1,276 | 1,755 |
| Other Liabilities + | 96 | 276 | 365 | 468 | 1,005 | 1,197 | 910 |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 | 8,586 |
| Fixed Assets + | 633 | 1,231 | 1,361 | 863 | 6,118 | 6,017 | 6,445 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 529 | 141 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 | 17 |
| Other Assets + | 195 | 722 | 314 | 356 | 1,305 | 1,742 | 1,983 |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 | 8,586 |
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -118 | -416 | -163 | -107 | -68 | 9 |
| Cash from Investing Activity + | -207 | -692 | -68 | 511 | -201 | -495 |
| Cash from Financing Activity + | 381 | 1,162 | 118 | -391 | 412 | 359 |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 164 | 430 | 108 | 130 | -13 | 6 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Public | 32.24% | 29.17% | 33.42% | 32.34% | 32.01% | 31.4% | 26.95% | 25.86% |
| Promoters | 37.76% | 34.25% | 29.78% | 29.77% | 29.93% | 30.48% | 30.48% | 30.47% |
| FII | 17.44% | 18.54% | 18.69% | 19.39% | 19.24% | 17.5% | 19.19% | 19.45% |
| DII | 12.56% | 18.03% | 18.09% | 18.48% | 18.8% | 20.61% | 23.37% | 24.2% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Onesource Specl Pharma L (this stock) | 18,464 | 1614.0 | 3.12 | -1.09% |
| Eris Lifesciences Limited | 18,448 | 24.7 | 4.45 | 18.7% |
| Syngene International Ltd | 17,935 | 67.5 | 3.7 | 7.78% |
| Caplin Point Lab Ltd. | 17,863 | 25.9 | 4.58 | 20.9% |
| Alivus Life Sciences Ltd | 17,803 | 50.6 | — | — |
| Pfizer Ltd | 17,601 | 115.0 | 12.74 | 19.8% |
| Shilpa Medicare Ltd | 19,392 | 60.6 | 7.04 | 9.3% |
Which Mutual Funds Hold Onesource Specl Pharma L?
Frequently Asked Questions about Onesource Specl Pharma L
Onesource Specl Pharma L (ONESOURCE) closed at ₹1,602.9 on NSE on 19 November 2026, up 16.7 (1.05%) from the previous close.
Onesource Specl Pharma L trades on the NSE (National Stock Exchange of India) under the symbol ONESOURCE.
Onesource Specl Pharma L has a trailing twelve-month P/E (price-to-earnings) ratio of 1614.0.
Onesource Specl Pharma L has a dividend yield of 0.0%.
Onesource Specl Pharma L's 52-week high is ₹1,918.0 and its 52-week low is ₹1,057.0.
Onesource Specl Pharma L has a market capitalisation of ₹18,464 crore.
Onesource Specl Pharma L has a TopFund Quality Score of 59/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Onesource Specl Pharma L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.